CAS: 1505484-82-1; Nemorexant
- 英文名称Nemorexant
- 中文名称[(2S)-2-(6-氯-7-甲基-1H-苯并咪唑-2-基)-2-甲基-1-吡咯烷基][5-甲氧基-2-(2H-1,2,3-三唑-2-基)苯基]甲酮
- IUPAC名称Methanone, ((2S)-2-(6-chloro-7-methyl-1H-benzimidazol-2-yl)-2-methyl-1-pyrrolidinyl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)-
- CAS编号1505484-82-1
- EINECS号:879-120-8
- FDA UNII编号:LMQ24G57E9
- 分子式:C23H23ClN6O2分子量:450.92
- 产品CID: 730732
- 同类组份化合物CAS1792993-84-0 (HCl)1505484-82-1 (free base)Daridorexant mesylate
物理性质
- 沸点747.6±70.0 °C(预测)
- 密度1.42±0.1 g/cm3(预测)
- pKa:10.47±0.30(预测)
- LogP:4.1
- 溶解性DMSO: ≥ 250 mg/mL (554.42 Mm)
- 外观形态固体-粉末
- 储存条件储存在 -20°C
- 产品应用该化合物是一种针对OX1R和OX2R的强大,选择性的双重或异见感受体对抗剂(DORA),其次纳米同源(K0.47 NM 用于OX1-R,0.93 NM用于OX2R)在体外受体约束性实验中显示出了亚甲酸酯的强力,选择性双倍或异性受体激素抗体(DORA),该抗体是针对OX1R 和OX2-R的,其亚纳米体对异性(KIK 0.47 NM 用来进行OX-1R和 0.93 NM) 的亲近性(KI) . 功能研究证实A-导致的钙(EXIN A) 以低纳米摩尔 IC50 值诱导的热度信号有效抑制了该物质, 支持强力阻断绝后刺激路径. 在活性, 刺激性中, DRIDOREXEXANTEXANT 和有利的安全剖面, 低依赖风险. 这些特性使得低度成为了研究或有希望感应力的有价值的研究工具.
欧盟法规
C&L通报合成工艺路线路线简述
海关参考信息
- 2903919090-氯苯
2905110000-甲醇
2912110000-甲醛
2912210000-苯甲醛 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:WO-2025215225-A1
优先权日:2024-04-12
标题:Method for the synthesis of 5-methoxy-2-(2h-1,2,3-triazol-2-yl)benzoic acid, a sodium salt of said acid as a synthetic intermediate, and use of the acid or the salt thereof in the preparation of daridorexant and certain intermediates in the synthesis thereof
发明人：AKHATOU ABDESLAM; BALLETTE ROBERTO
权利人:MOEHS IBERICA S L
摘要:The invention relates to a method for the synthesis of 5-methoxy-2-(2H-1,2,3-triazol-2-yl)benzoic acid, to the sodium salt of said acid as a synthetic intermediate, and to the use of the acid or the salt thereof in the preparation of daridorexant and certain intermediates in the synthesis thereof.
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Winter Y, Arnaldi D. Daridorexant: exploring its role in the treatment of insomnia disorder. Expert Rev Neurother. 2026 Apr;26(4):325-340. doi: 10.1080/14737175.2026.2639557. Epub 2026 Mar 15. 2025 Oct. Report No.: SR0862. 26(17):8700. doi: 10.3390/ijms26178700.
4: Ferini-Strambi L, Arnaldi D, Bonanni E, Cicolin A, Gigli GL, Liguori C, Lombardi C, Parrino L, Provini F, Puligheddu M, Romigi A, Silvestri R, Palagini L. Daridorexant and Insomnia in Clinical Practice: A Nominal Group Technique Consensus Study among Italian Sleep and Insomnia Experts. Curr Neuropharmacol. 2026;24(1):135-149. doi: 10.2174/011570159X367329250717020016. 15(1):211. doi: 10.1038/s41398-025-03439-8.
6: Oldham MA, Lander HL, Choi JJ, Gloff MS, Knight PA, Nadler JW. Dual Orexin Receptor Antagonists for Delirium: A Scoping Review and Feasibility Trial of Daridorexant. J Acad Consult Liaison Psychiatry. 2026 Jan-Feb;67(1):61-70. doi: 10.1016/j.jaclp.2025.05.003. Epub 2025 May 13.
合成参考文献
摘要:21 CFR Sections 1308.11-1308.15 https://www.ecfr.gov/current/title-21/chapter-II/part-1308
📝 需求与反馈
尽可能描述清楚需求与问题信息
